| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5616599 | COSETTE | Angiotensin II antagosist 1-biphenylmethylimidazole compounds and their therapeutic use |
Apr, 2016
(8 years ago) | |
|
US5616599 (Pediatric) | COSETTE | Angiotensin II antagosist 1-biphenylmethylimidazole compounds and their therapeutic use |
Oct, 2016
(7 years ago) | |
| US6878703 | COSETTE | Pharmaceutical composition |
Nov, 2021
(2 years ago) | |
|
US6878703 (Pediatric) | COSETTE | Pharmaceutical composition |
May, 2022
(1 year, 11 months ago) | |
Benicar is owned by Cosette.
Benicar contains Olmesartan Medoxomil.
Benicar has a total of 4 drug patents out of which 4 drug patents have expired.
Expired drug patents of Benicar are:
- US5616599
- US5616599*PED
- US6878703
- US6878703*PED
Benicar was authorised for market use on 25 April, 2002.
Benicar is available in tablet;oral dosage forms.
Benicar can be used as use as an antihypertensive agent, treatment of hypertension.
The generics of Benicar are possible to be released after 19 May, 2022.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population(NPP) | Feb 04, 2013 |
| Pediatric Exclusivity(PED) | Aug 04, 2013 |
Drugs and Companies using OLMESARTAN MEDOXOMIL ingredient
Market Authorisation Date: 25 April, 2002
Treatment: Use as an antihypertensive agent; Treatment of hypertension
Dosage: TABLET;ORAL
How can I launch a generic of BENICAR before it's drug patent expiration?
More Information on Dosage
BENICAR family patents
